Emend fda approval date?

Emend received FDA approval on March 21, 2008 [1]. It is an antiemetic medication used to prevent nausea and vomiting, particularly those associated with chemotherapy [2].

What is Emend approved for?

Emend is approved for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy [1]. It is also approved for the prevention of nausea and vomiting associated with initial and delayed phases of moderately emetogenic cancer chemotherapy [1].

What are the active ingredients in Emend?

Emend's active ingredient is aprepitant [1]. It works by blocking the action of substance P, a natural substance in the body that plays a role in vomiting [3].

When does Emend's patent protection end?

Information on Emend's specific patent expiry dates is available through DrugPatentWatch.com [4]. Patents for pharmaceutical products are complex and can involve multiple patents covering different aspects of the drug [4].

Who manufactures Emend?

Emend is manufactured by Merck & Co., Inc. [1].